{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:07:19Z","timestamp":1793351239212,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Neopharma Japan Co., Ltd.","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Glucocorticoids are an important class of medication for patients with adult-onset Still disease (AOSD), however, relapse following glucocorticoid reduction and adverse events due to long-term effects of glucocorticoid are still problematic. It is of course essential to minimize the risk of treatment. Immunosuppressive therapies such as methotrexate and biologics including tocilizumab are used in glucocorticoid-dependent patients with AOSD, but no second-line treatments for patients with glucocorticoid dependence have been established yet. Given that these drugs also have the potential to cause adverse events, alternative treatments are sought. Recently, elevated heme oxygenase-1 (HO-1) has been reported in the serum of patients with AOSD, suggesting that HO-1 activity contributes to AOSD pathogenesis and may represent a new therapeutic target for the treatment of AOSD. The amino acid 5-aminolevulinic acid (5-ALA) is a non-proteinogenic \u03b4 amino acid in human body. An addition of ferrous iron to 5-ALA enhances heme biosynthesis. The increase in heme in vivo induces HO-1 production, a heme-degrading enzyme. Elevated HO-1 has been suggested to contribute to the pathogenesis of AOSD, and administration of 5-ALA and ferrous iron may be a potential treatment for AOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design:<\/jats:title>\n            <jats:p>This study is a single-arm, open-label pilot intervention study using clinical endpoints to investigate the effects of oral 5-ALA with sodium ferrous citrate on glucocorticoid reduction in patients with AOSD receiving glucocorticoid therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This pilot intervention study will provide evidence regarding the effectiveness and safety of 5-ALA\/sodium ferrous citrate as a potential new therapeutic agent for glucocorticoid-dependent patients with AOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This study was registered in the Japan Registry of Clinical Trials (https:\/\/jrct.niph.go.jp) on January 14, 2020 as jRCTs071190042.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000022708","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T21:59:16Z","timestamp":1607637556000},"page":"e22708","source":"Crossref","is-referenced-by-count":4,"title":["Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease"],"prefix":"10.1097","volume":"99","author":[{"given":"Remi","family":"Sumiyoshi","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"},{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult Still's disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/14397595.2017.1422231","article-title":"Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: a multicenter retrospective study","volume":"28","author":"Kirino","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/2211-5463.12729","article-title":"5-ALA\/SFC enhances HO-1 expression through the MAPK\/Nrf2 antioxidant pathway and attenuates murine tubular epithelial cell apoptosis","volume":"9","author":"Liu","year":"2019","journal-title":"FEBS Open Bio"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R8-20230916","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07853890.2014.971052","article-title":"Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options","volume":"47","author":"Kadavath","year":"2015","journal-title":"Ann Med"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003495-200868030-00005","article-title":"Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances","volume":"68","author":"Kontzias","year":"2008","journal-title":"Drugs"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1165\/ajrcmb.27.1.4862","article-title":"Heme oxygenase-1: the \u201cemerging molecule\u201d has arrived","volume":"27","author":"Morse","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1073\/pnas.0308083100","article-title":"Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.intimp.2015.11.034","article-title":"5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction","volume":"37","author":"Fujino","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"8294805","DOI":"10.1155\/2016\/8294805","article-title":"The safety and tolerability of 5-aminolevulinic acid phosphate with sodium ferrous citrate in patients with type 2 diabetes mellitus in Bahrain","volume":"2016","author":"Al-Saber","year":"2016","journal-title":"J Diabetes Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T04:11:43Z","timestamp":1694837503000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022708"}},"subtitle":["Study protocol for clinical trial (SPIRIT compliant)"],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":18,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022708","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}